ABOUT SKYRIZI

Jump to:

Experience
Mechanism of Action (MOA)

EXPERIENCE

#1 prescribed biologic in Crohn’s and UC

SKYRIZI Is the #1 Prescribed Biologic
in Crohn’s Disease + Ulcerative Colitis 2*

*Source: Symphony Health, an ICON plc Company, IDV®; Total Combined Prescription Count from January 2025 to March 2025.2

EXPERIENCE

#1 prescribed biologic in Crohn’s and UC

SKYRIZI Is the #1 Prescribed Biologic
in Crohn’s Disease + Ulcerative Colitis 2*

*Source: Symphony Health, an ICON plc Company, IDV®; Total Combined Prescription Count from January 2025 to March 2025.2

SKYRIZI Has Exceptional Immunology Experience3

Approved in 4 Indications: Plaque Psoriasis (Ps), Psoriatic Arthritis (PsA), Crohn’s Disease, and Ulcerative Colitis (UC)1

448,930

Patients Prescribed Worldwide
Since 2019 Starting With Ps4†

†Source: Symphony Health, an ICON plc Company, IDV®; September 1, 2016 to November 30, 2024.

69,794

Patients Prescribed in IBD in the US5†

#1 prescribed first-line biologic by rheumatologists for PsA

‡"First-line" is defined as the first biologic prescription among patients who have not been prescribed biologics in the last 3 years. §Source: IQVIA (NPA, NSP) and Symphony Health data through February 2025.6

#1 prescribed branded systemic by dermatologists for patients with psoriatic disease

IISource: Integrated Symphony Health as of 3/2024.7

The term branded systemic is defined as systemic drugs that are sold by a specific name or trademark and protected by patent. OTC stands for over-the-counter medications.

IBD=inflammatory bowel disease; NPA=National Prescription Audit; NSP=National Sales Perspectives.

MECHANISM OF ACTION (MOA)

How SKYRIZI Works

SKYRIZI: an IL-23p19–Specific Inhibitor for the Treatment of IBD1,8-10

MOA image

SKYRIZI is a humanized IgG1 monoclonal antibody that specifically targets the p19 subunit of IL-23, a cytokine ​known to play a key role in driving inflammatory autoimmune diseases, such as IBD.

  • Regions of the SKYRIZI antibody were modified and studied in preclinical in vitro and animal models
  • Specific pharmacokinetic properties of SKYRIZI studied:
  1. Half-life (~21 days in IBD)
  2. Stability and bioavailability
  3. Immunogenicity

 

The clinical significance of these findings/modifications is unknown.

FcγRs=receptors for the Fc fragment of immunoglobulin G; IBD=inflammatory bowel disease; IgG=immunoglobulin G; IL-23=intereukin-23; IL-23p19=interleukin-23 subunit alpha; NOD2=nucleotide-binding oligomerization domain-containing protein 2; Th1=T helper 1 cell; Th17=T helper 17 cell.

Recommended for You

Efficacy in Crohn’s Disease

View Crohn’s Efficacy Data

Efficacy in Ulcerative Colitis

View UC Efficacy Data

SKYRIZI Dosing

View Dosing Info